Abbvie, Inc. (ABBV) Tops Q2 EPS by 6c; Guides Q3 EPS to Strong Side
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
UPDATE: UBS Upgrades Abbvie (ABBV) to Buy
July 28, 2014 8:14 AM EDT(Updated - July 28, 2014 10:40 AM EDT)
UBS upgraded Abbvie (NYSE: ABBV) from Neutral to Buy with a price target of $67 (from $57). Analyst Marc Goodman noted compelling risk/reward.
"Upgrading ABBV to a Buy rating and PT of $67 with 4-fold investment thesis (1) We like the Shire deal. It's accretive, diversifies earnings... More
